COHANCEPharmaceuticals
COHANCE LIFESCIENCES LTD — Profit & Loss Statement
₹301.45
-1.13%
COHANCE LIFESCIENCES LTD Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 4.78 Cr | 23.77 Cr | — |
| Tax Rate For Calcs | 0.23 | 0.26 | 0.27 | 0.32 | — |
| Normalized EBITDA | 433.76 Cr | 467.72 Cr | 602.51 Cr | 638.70 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Reconciled Depreciation | 77.49 Cr | 54.60 Cr | 46.46 Cr | 38.26 Cr | — |
| Reconciled Cost Of Revenue | 305.29 Cr | 315.04 Cr | 586.19 Cr | 572.29 Cr | — |
| EBITDA | 433.76 Cr | 467.72 Cr | 620.53 Cr | 712.92 Cr | — |
| EBIT | 356.27 Cr | 413.12 Cr | 572.54 Cr | 673.82 Cr | — |
| Net Interest Income | -12.35 Cr | -7.45 Cr | -6.98 Cr | -8.46 Cr | — |
| Interest Expense | 12.35 Cr | 7.45 Cr | 12.81 Cr | 6.23 Cr | — |
| Normalized Income | 264.77 Cr | 300.28 Cr | 398.05 Cr | 403.35 Cr | — |
| Net Income From Continuing And Discontinued Operation | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Total Expenses | 899.87 Cr | 700.14 Cr | 804.81 Cr | 763.81 Cr | — |
| Diluted Average Shares | 25.34 Cr | 25.45 Cr | 25.46 Cr | 25.46 Cr | — |
| Basic Average Shares | 25.17 Cr | 25.45 Cr | 25.46 Cr | 25.46 Cr | — |
| Diluted EPS | 10.45 | 11.80 | 16.16 | 17.83 | — |
| Basic EPS | 10.52 | 11.80 | 16.16 | 17.83 | — |
| Diluted NI Availto Com Stockholders | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Net Income Common Stockholders | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Net Income Including Noncontrolling Interests | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Net Income Continuous Operations | 264.77 Cr | 300.28 Cr | 411.29 Cr | 453.80 Cr | — |
| Tax Provision | 79.15 Cr | 105.39 Cr | 148.44 Cr | 213.78 Cr | — |
| Pretax Income | 343.92 Cr | 405.67 Cr | 559.73 Cr | 667.59 Cr | — |
| Other Non Operating Income Expenses | 58.56 Cr | 61.91 Cr | 0.96 Cr | 1.10 Cr | — |
| Net Non Operating Interest Income Expense | -12.35 Cr | -7.45 Cr | -6.98 Cr | -8.46 Cr | — |
| Interest Expense Non Operating | 12.35 Cr | 7.45 Cr | 12.81 Cr | 6.23 Cr | — |
| Operating Income | 297.71 Cr | 351.21 Cr | 526.30 Cr | 543.20 Cr | — |
| Operating Expense | 594.58 Cr | 385.10 Cr | 218.61 Cr | 191.52 Cr | — |
| Other Operating Expenses | 267.53 Cr | 195.27 Cr | 25.03 Cr | 17.92 Cr | — |
| Depreciation And Amortization In Income Statement | 77.49 Cr | 54.60 Cr | 47.99 Cr | 39.10 Cr | — |
| Depreciation Income Statement | 77.49 Cr | 54.60 Cr | 47.59 Cr | 38.71 Cr | — |
| Gross Profit | 892.29 Cr | 736.31 Cr | 744.92 Cr | 734.72 Cr | — |
| Cost Of Revenue | 305.29 Cr | 315.04 Cr | 586.19 Cr | 572.29 Cr | — |
| Total Revenue | 1.20K Cr | 1.05K Cr | 1.33K Cr | 1.31K Cr | — |
| Operating Revenue | 1.20K Cr | 1.05K Cr | 1.33K Cr | 1.31K Cr | — |
| Total Unusual Items | — | 47.21 Cr | 18.01 Cr | 74.22 Cr | 3.36 Cr |
| Total Unusual Items Excluding Goodwill | — | 47.21 Cr | 18.01 Cr | 74.22 Cr | 3.36 Cr |
| Interest Income | — | 2.02 Cr | 5.83 Cr | 0.07 Cr | 0.27 Cr |
| Rent Expense Supplemental | — | 0.97 Cr | 0.00 | 61000.00 | 0.35 Cr |
| Special Income Charges | — | 2.30 Cr | 2.33 Cr | -0.20 Cr | 0.03 Cr |
| Other Special Charges | — | -5.53 Cr | -2.33 Cr | 0.20 Cr | -0.03 Cr |
| Restructuring And Mergern Acquisition | — | 3.22 Cr | 0.00 | — | — |
| Interest Income Non Operating | — | 2.02 Cr | 5.83 Cr | 0.07 Cr | 0.27 Cr |
| Amortization | — | 0.41 Cr | 0.40 Cr | 0.39 Cr | 0.39 Cr |
| Selling General And Administration | — | 29.52 Cr | 36.57 Cr | 36.62 Cr | 26.58 Cr |
| Selling And Marketing Expense | — | 10.35 Cr | 17.64 Cr | 19.80 Cr | 10.53 Cr |
| General And Administrative Expense | — | 19.17 Cr | 18.93 Cr | 16.82 Cr | 16.05 Cr |
| Rent And Landing Fees | — | 0.97 Cr | 0.00 | 61000.00 | 0.35 Cr |
| Total Other Finance Cost | — | — | 7.37 Cr | 2.30 Cr | 2.52 Cr |
| Research And Development | — | — | 8.59 Cr | 10.35 Cr | 11.06 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on COHANCE LIFESCIENCES LTD
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.